Relay Platform

Unlocking protein motion to transform drug discovery for previously intractable targets.

by Relay Therapeutics · Drug Discovery AI

Executive Summary

The Relay Dynamo™ Platform is a proprietary, integrated R&D engine used by Relay Therapeutics to accelerate small molecule drug discovery. It leverages advanced machine learning, molecular dynamics simulations, and experimental techniques to understand protein motion, enabling the design of precision medicines for oncology and genetic diseases. The platform's differentiation lies in its ability to identify and drug previously intractable protein targets by focusing on their dynamic behavior rather than static structures, providing a significant advantage in developing novel therapeutics.

Use Cases

  • Identifying novel drug targets by understanding protein dynamics.
  • Designing small molecule drugs with improved specificity and potency.
  • Optimizing lead compounds for desired therapeutic characteristics.
  • Accelerating the drug discovery process from hit identification to lead optimization.
  • Addressing previously intractable disease pathways in oncology and genetic diseases.

Features

Visibility

  • Protein Dynamics Visualization: Visualizes the three-dimensional motion of proteins over biologically relevant timescales to reveal dynamic conformations and binding sites.
  • Experimental Data Integration: Integrates data from Cryo-EM, X-ray crystallography, and other biophysical experiments for a comprehensive understanding of protein structure and function.
  • Computational Screening Results: Displays results from virtual screens of billions of molecules, highlighting potential chemical starting points and their predicted interactions.

Intelligence

  • AI-Powered Target Identification: Utilizes machine learning to identify novel binding sites and previously 'undruggable' protein targets by analyzing protein motion.
  • Molecular Dynamics Simulations: Performs long-timescale molecular dynamics simulations to generate virtual simulations of full-length protein movement.
  • Predictive Drug Property Modeling: Predicts and designs compounds with desired characteristics such as potency, selectivity, and bioavailability, accelerating lead optimization.
  • DNA-Encoded Library (DEL) ML: Incorporates machine learning powered DNA-encoded library (REL-DEL) data to rapidly identify and prioritize chemical starting points.

Support

  • Internal Scientific Support: Dedicated internal teams provide scientific and technical support to researchers utilizing the Dynamo™ platform.
  • Platform Development & Maintenance: Continuous internal development, updates, and maintenance ensure the platform remains at the cutting edge of computational and experimental capabilities.

Technical Specifications

Architecture
Cloud-native, high-performance computing (HPC) environment leveraging specialized supercomputers and cloud services.
Deployment
Internal/Proprietary Cloud/SaaS
Authentication
Internal corporate authentication mechanisms
API Available
No
MCP Server
No

Infrastructure

  • AWS
  • GCP
  • D.E. Shaw Research Anton 2 supercomputer

AI/ML Stack

  • Machine Learning
  • Molecular Dynamics Simulations
  • Physics-based Simulations
  • Computational Biology
  • Deep Learning

Integrations

  • Cryo-EM
  • Molecular Dynamics

Security & Compliance

Certifications: Internal compliance with pharmaceutical R&D data security standards

Encryption: Standard enterprise-grade encryption for data at rest and in transit.

Pricing

Model
Not applicable (internal proprietary platform)
Starting Price
Not applicable (internal proprietary platform)
Target Customer
Relay Therapeutics (internal use)
Contract Type
Not applicable (internal proprietary platform)
Free Trial
No (credit card required)

About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies. They focus on making small molecule medicines against precision medicine targets, with an initial focus on oncology and genetic disease.

Founded: 2016 · Headquarters: Cambridge, Massachusetts, USA · Employees: 51-200 · Public